Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the best stocks to invest in for a quick return.

Robotic arms performing diagnostic tests in a healthcare technology lab.

Citi initiated coverage on Solid Biosciences Inc. (NASDAQ:SLDB) with a ‘Buy’ rating, setting its price target at $14 on June 26, 2025. Citing strong potential in the Duchenne Muscular Dystrophy (DMD) market, the analyst discussed a compelling valuation gap, with the company’s current $100 million total firm value sitting well below its projected peak U.S. sales potential of around $3 billion.

Furthermore, safety concerns recently erupted surrounding a competitor’s DMD therapy, which has resulted in increased attention toward Solid Biosciences Inc.’s (NASDAQ:SLDB) SGT-003 because of no signs of liver toxicity caused by it. Thus, several analysts maintain ‘Buy’ or ‘Overweight’ ratings, with price targets ranging from $14 to $20.

The company is focused on developing gene therapies for neuromuscular and cardiac conditions, with a pipeline led by SGT-003 for DMD. Moreover, its strong cash position backs Solid Biosciences Inc.’s (NASDAQ:SLDB) next phase of development. It is one of the best stocks.

READ NEXT: 7 Best Fertilizer Stocks to Buy According to Hedge Funds and Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates.

Disclosure: None.